2023-2024 Grant Cycle Application Instructions

Letter of Intent Due: November 15, 2023 (by 5:00 p.m. Eastern Time)
Full Proposal Due: April 12, 2024 (by 5:00 p.m. Eastern Time)

Submit via Proposal Central:
https://proposalcentral.com
Recommended Browsers: Google Chrome or Mozilla Firefox

For additional questions or information, please email:
submissions@osinst.org

Published by the Osteosarcoma Institute on September 1, 2023
TABLE OF CONTENTS

THE OSTEOSARCOMA INSTITUTE OVERVIEW ......................................................................................... 3
  MISSION .................................................................................................................................................. 3
  HISTORY .................................................................................................................................................. 3
  GRANT STRATEGY .................................................................................................................................. 3

GRANT PROGRAM DESCRIPTIONS ........................................................................................................ 4
  CLINICAL TRIALS .................................................................................................................................... 4
    SCOPE OF PROPOSAL ............................................................................................................................ 4
    BUDGET ................................................................................................................................................ 4
  CORRELATIVE SCIENCE .......................................................................................................................... 4
    SCOPE OF PROPOSAL ............................................................................................................................ 4
    BUDGET ................................................................................................................................................ 4
  PRECLINICAL/TRANSLATIONAL ............................................................................................................. 5
    SCOPE OF PROPOSAL ............................................................................................................................ 5
    BUDGET ................................................................................................................................................ 5

NEW FOR 2023-2024 GRANT CYCLE: HIGH-RISK/HIGH-IMPACT ............................................................ 5
  SCOPE OF PROPOSAL ............................................................................................................................ 5
  BUDGET ................................................................................................................................................ 5

GENERAL INSTRUCTIONS FOR ALL GRANT PROGRAMS .................................................................... 6
  GRANT PROCESS OVERVIEW .................................................................................................................. 6
  APPLICATION DEADLINES AND REVIEW TIMELINES ......................................................................... 6
  ELIGIBILITY CRITERIA (MUST BE MET AT THE TIME OF SUBMISSION) ................................................. 6
  INDIRECT COSTS ....................................................................................................................................... 7
  APPLICATION SUBMISSION INSTRUCTIONS ........................................................................................... 7
  FORMATTING INSTRUCTIONS FOR ATTACHMENTS .............................................................................. 7
  CONTACTS ............................................................................................................................................... 7

SUMMARY OF GRANT AGREEMENT TERMS ......................................................................................... 8
  GENERAL .................................................................................................................................................. 8
  FUNDING SCHEDULE ............................................................................................................................... 8
  REPORTING .............................................................................................................................................. 8
  PUBLICATION AND PUBLICITY ................................................................................................................ 8

GRANT PROGRAM-SPECIFIC APPLICATION INSTRUCTIONS ................................................................. 9
  CLINICAL TRIALS GRANT PROGRAM ..................................................................................................... 9
    LETTER OF INTENT (LOI) INSTRUCTIONS ............................................................................................ 9
    FULL PROPOSAL INSTRUCTIONS ........................................................................................................ 10
  CORRELATIVE SCIENCE • PRECLINICAL/TRANSLATIONAL • HIGH-RISK/HIGH-IMPACT ..................... 11
    LETTER OF INTENT (LOI) INSTRUCTIONS ............................................................................................ 11
    FULL PROPOSAL INSTRUCTIONS ........................................................................................................ 12

ADDITIONAL RESOURCES .................................................................................................................... 13
  2023-2024 GRANT CYCLE ....................................................................................................................... 13
  NEWSLETTER SIGN UP ............................................................................................................................ 13
  RESEARCHER RESOURCES .................................................................................................................... 13
  THE FRONTLINE BLOG ........................................................................................................................... 13
MISSION
To dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the
most promising and breakthrough osteosarcoma clinical trials and science.

HISTORY
The Osteosarcoma Institute (OSI) was established in 2017 with the goal of improving the outcomes of patients with
osteosarcoma. It was envisioned by the What Would Willie Want (QuadW) Foundation, which was created in 2005 to
honor the memory of Willie Tichenor, who lost his life to osteosarcoma at age 19. QuadW convened a conference in
2015 to challenge experts in osteosarcoma research to expedite work that could improve outcomes. This meeting led to
the formation of the OSI, with a foundational grant from QuadW.

GRANT STRATEGY
The OSI is a science-driven organization whose strategy is guided by its active and engaged Strategic Advisory Board of
preeminent physicians and other researchers from academia and industry. In pursuit of its mission, the OSI employs a multi-
faceted strategy in which grant funding plays an important role. Our grant programs provide both immediate hope to
patients through clinical trials and long-term hope through earlier-stage translation of scientific ideas that have the potential
to result in a new treatment. Our correlative science grants are designed to answer critical questions that are too often
ignored during clinical trials due to lack of funds: Is the drug under study having the biological effect in patients that it was
hypothesized to have based on preclinical data? If not, why not? With this information, even a failed clinical trial can point
the way to an advance. Our fourth category, High Risk/High Impact grants, exists to enable the study of novel, untested but
intriguing ideas that would otherwise be rejected by the customary, risk-averse criteria of grant proposal evaluation. The
objective of all our preclinical grants is to identify and advance scientific ideas toward the clinic.

Today, the OSI has committed $6.5 million toward a comprehensive portfolio of 14 funded studies. We maintain a high
level of involvement and accountability with our grantees through regular and rigorous progress reporting.
CLINICAL TRIALS

SCOPE OF PROPOSAL
The primary objective of proposed Phase I/II or Phase II clinical trials should be to improve event free survival (EFS) at 4 months, beyond historical rates known to be in the range of 12%. The proposed trial may be carried out in a single institution, a clinical trial consortium, or through an existing clinical trial infrastructure. OSI will not prioritize the launch of new infrastructures to conduct clinical trials. Please provide specific timetables for protocol development, regulatory approvals, industry agreements, IRB approvals, activation, accrual, and reporting. We will consider the applicant’s history of efficiently entering agreements, opening trials, and meeting accrual expectations for trials of relapsed osteosarcoma patients, with the expectation that results will be available within three years of trial initiation. Other desirable characteristics for proposals include:

- Answering an important question
- Strong preclinical rationale
- Rigorous trial design and correlative endpoints to allow for productive failure.
- Budget reasonableness (per patient and total)
- Leverage from concurrent financial support of the trial (e.g., direct institutional support, industry and/or philanthropic support, securing drug, etc.)

BUDGET
Up to $800,000 total over two to three years.

CORRELATIVE SCIENCE

SCOPE OF PROPOSAL
Correlative studies should seek to generate data in support of clinical trials seeking to improve event free survival of recurrent and metastatic osteosarcoma patients. Our highest priority for correlative science proposals is those that will create the opportunity, should the associated clinical trial fail, to understand the reasons for that failure and allow for productive iteration of the approach. Nonetheless, proposals may include hypothesis testing and/or exploratory, hypothesis generating elements, but all proposals should include/prioritize the following:

- The generation of new biology data associated with a clinical trial that will improve our understanding of osteosarcoma metastasis and/or accelerate the launch of future clinical or translational osteosarcoma studies.
- Power analyses demonstrating the number of samples from patients needed to answer each correlative question proposed to be answered, and the rationale for asserting that the required samples will be obtained.
- Preliminary data demonstrating technical ability to apply desired technology for biological analysis to relevant osteosarcoma biospecimens.

BUDGET
From $250,000 – $500,000 total over two years.
PRECLINICAL/TRANSLATIONAL

SCOPE OF PROPOSAL
A translational imperative for the OSI is to cultivate and support a research agenda that will identify biological dependencies in the disease that can be targeted in patients. This research agenda will ideally include the use of novel laboratory approaches and bioinformatic tools applied to osteosarcoma cells, a diversity of in vivo models across species and human patient samples. Furthermore, we believe these dependencies will likely impact a variety of potential phenotypes associated with the disease, including metastatic proclivity, DDR in the context of a structurally complex genome, and resistance to first generation T cell checkpoint blockade. Despite an urgency for preclinical translation, we realize and value foundational research studies that will identify the desired biological dependencies/targets.

BUDGET
Up to $500,000 total for two years.

NEW FOR 2023-2024 GRANT CYCLE: HIGH-RISK/HIGH-IMPACT

SCOPE OF PROPOSAL
This new pilot grant program is for bold new ideas that may fall within any part of a drug development path, and that seek to deliver curative outcomes to patients with osteosarcoma. These proposals will be most valued based on their innovation and the likelihood that the approach will target a true dependency in osteosarcoma.

A focus on limiting risk is common in life-sciences grantsmanship. This risk mitigation is affected in several ways during the research proposal review process including a requirement for extensive preliminary data and high value placed on investigator pedigree and past success. The OSI recognizes the possibility that this risk-averse strategy might inadvertently screen out projects that could deliver desired high-impact breakthroughs to patient outcomes. Thus, this grant program for bold new innovations will relax this historical priority on risk mitigation and embrace higher risk studies. Indeed, this grant program will prioritize many principles associated with angel investments in innovations and entrepreneurship.

This high-risk/high-impact osteosarcoma drug development research will replace the conventional life sciences grant review with these alternative guardrails:

- Bold ideas that will generate hints of success or failure in 12 months.
- Applicant must propose a new research direction, not a continuation of ongoing funded research.
- While preliminary data are not required, the applicant must demonstrate feasibility of the research plan.
- Rigorous and repeated in-person grant progress reviews (quarterly) that will replace the priority on preliminary data and will be used to guide ongoing direction and distribution of research support.

A successful high-risk/high-impact grant proposal should have the following characteristics:

- A proposal that may mature into a successful traditional OSI grant submission following funding of high-risk/high-impact grant.
- An existing transaction that makes the development of a therapeutic asset in biopharma feasible.
- Will deliver new knowledge sufficient to launch a translational development plan with institutions, investigators, or commercial companies.
- Support for non-PI salary or other needed long-term expenses that cannot be managed by the planned quarterly review and payment approach.

BUDGET
From $50,000 – $125,000 total over one year.
GENERAL INSTRUCTIONS FOR ALL GRANT PROGRAMS

GRANT PROCESS OVERVIEW
The OSI utilizes a two-stage grant process. In September of each year, we issue a call for Letter of Intent (LOI) proposals. In late fall, we convene expert review committees to evaluate the LOIs and select finalists who progress to the second stage and are invited to submit full proposals during the spring. The full proposals are evaluated, and grants are awarded in the summer.

We do not limit our work by geography or primary institutions. Instead, we invite the brightest minds in the field to apply for funding for research studies and revolutionary trials of unexplored aspects of osteosarcoma. In recognition of the effort to submit an LOI and full proposal, and with the objective of improving future applications, every applicant receives detailed feedback about their submission from our reviewers following the LOI and full proposal stages. We have seen that this work has resulted in higher quality submissions over the past few years.

APPLICATION DEADLINES AND REVIEW TIMELINES

<table>
<thead>
<tr>
<th>Application Stage</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Intent Deadline</td>
<td>November 15, 2023</td>
</tr>
<tr>
<td>Letter of Intent Decision</td>
<td>January 2024</td>
</tr>
<tr>
<td>Full Grant Submission Deadline</td>
<td>April 12, 2024</td>
</tr>
<tr>
<td>Awardee Notifications</td>
<td>Summer 2024</td>
</tr>
</tbody>
</table>

Note: The following application procedures and timeline constitute the primary OSI grantmaking cycle, which is the preferred method of applying for a grant. OSI recognizes that not all projects are compatible with these time restrictions; accordingly, we consider out-of-cycle proposals on a case-by-case basis. Additionally, the OSI has a Discretionary Grant Program for new and innovative ideas that need a relatively small, but timely investment to establish feasibility for further development in osteosarcoma. Please visit the OSI website here for more information on off-cycle and discretionary grant programs.

ELIGIBILITY CRITERIA (MUST BE MET AT THE TIME OF SUBMISSION)

- Funds must be granted to nonprofit/charitable institutions or organizations.
- Grantee organization does not need to be based in the United States.
  - However, in order to fund a foreign entity, the OSI requires documentation that if the entity were a United States-based organization, the entity would qualify as a charitable organization. This is usually relatively straightforward when dealing with entities in countries with a tax regime similar to the U.S. by way of a government-issued letter or other document designating the entity as a charitable institution or as performing a charitable purpose (for example, research or education). It might also be a determination from the relevant taxing authority that the entity qualifies for tax-deductible contributions.
- Applicants need not be United States citizens.
- Applicants must have an MD, PhD, MD/PhD, or equivalent and be appointed as faculty (or equivalent) at an academic institution.
- Applicants must have a track record of publication and funding productivity that demonstrates the project can be accomplished by the investigators.
- Applicant must propose a new research direction, not a continuation of ongoing funded research.
  - All established researchers requesting funds should show how their project is a departure from ongoing funded work. New projects may be an extension of other work but cannot overlap any funded studies unless the applicant clearly demonstrates that new funding will not duplicate existing support.
- Applicants selected for funding will permit OSI to publicize the grant for fundraising purposes, including, but not limited to a five-minute video discussing the research project, photos of lab, and photos of children participating in clinical trials, where applicable.
- Applications that do not follow the specific grant application instructions and/or submission process will not be considered.
- Applications received after the due date will not be considered.
- Applications which do not fall under the OSI mission will not be considered.
- Resubmissions: Only one resubmission of a previously reviewed application is permitted.
GRANT INSTRUCTIONS FOR ALL PROGRAMS (CONTINUED)

INDIRECT COSTS
Indirect costs may not exceed 10% of the total project budget (including indirect costs).

APPLICATION SUBMISSION INSTRUCTIONS
First time users must register as a new user in ProposalCentral to begin the application process. The recommended browsers for accessing the application are Google Chrome and Mozilla Firefox. Only applicants who submit an LOI and are approved may submit a full proposal. The PI will be notified via email if the LOI is approved or rejected. If approved, the PI will then have access to the full proposal in ProposalCentral. The PI who submits the LOI should be the same PI that submits the full proposal.

To locate the OSI Grant Programs, select the “Grant Opportunities” tab and enter “Osteosarcoma Institute” in the search box. The application form is available by clicking “Apply Now” on the appropriate line for the following grant programs:

- Clinical Trials Grant Program
- Correlative Science Grant Program
- Preclinical/Translational Grant Program
- High-Risk/High-Impact Grant Program

Note: Access can be granted to other users by using the “Enable other users to access this proposal” link.

FORMATTING INSTRUCTIONS FOR ATTACHMENTS

- Calibri or Times New Roman Font (minimum 11-point font for text and no smaller than 9-point font for figures, legends, and tables).
- Single-spaced text is acceptable, and space between paragraphs is recommended.
- In the Project Description, pages must be numbered consecutively.
- 0.75-inch minimum margin.
- Only PDF files are accepted.

CONTACTS

- ProposalCentral Customer Support: pcsupport@altum.com / Phone: 800.875.2562
- The Osteosarcoma Institute: submissions@osinst.org
SUMMARY OF GRANT AGREEMENT TERMS

Agreement with the following is required to receive an OSI grant. Please ensure that you and your institution can accept these terms. This section is for informational purposes only – the grant will be governed by a formal written agreement negotiated between the grantee and OSI which will be the controlling, authoritative document.

GENERAL
Customary organizational assurances from the lead institution regarding such matters as, as applicable, adherence to GLP, compliance with the Animal Welfare Act and applicable chapters of the Public Health Service Policy on Humane Care and Use of Laboratory Animals, subcontracting including the requirement that subcontractors comply with the terms of the grant agreement, and other matters as are typically covered in a research grant agreement.

We desire that the project work start as quickly as possible and are intent on an expeditious path to execution of the grant agreement with no unresolved contingencies. In negotiating the grant agreement, your institution must commit to assign persons with sufficient authority to avoid multi-level, multi-step approvals and meet the contract execution timelines. Any subcontracts must be fully executed before grant funding and must be reviewed and approved by the OSI.

FUNDING SCHEDULE
Grant funding typically includes an initial, start-up payment for a portion of the full grant amount. The initial payment will be due only after grantee, in consultation with the PI, advises OSI that work on the project is ready to begin. Subsequent scheduled grant payments are subject to the receipt by OSI of scheduled interim progress reports demonstrating satisfactory progress toward the completion of the proposed research aims/objectives and expenditures consistent with the budget.

Grants are not renewable; one no-cost extension may be requested.

REPORTING
During the grant term, interim written reports detailing progress on each specific aim and expenditures compared to budget are required every six months. In addition, an annual, in-person or, at OSI’s option, teleconference project presentation is required. Travel costs associated with in-person presentations will be reimbursed.

For clinical trials, grantee will provide OSI with timely adverse event reporting.

Customary confidentiality provisions will apply.

PUBLICATION AND PUBLICITY
Subject to reasonable and customary intellectual property considerations, PI will agree to publicize the results of the project at scientific conferences and use reasonable best efforts to have results published in a scientific journal. The OSI support of the project will be cited.

Grantee will permit OSI to publicize the grant, including a synopsis of the project, identifying the PI and institution, and allowing the use, solely for this purpose, of grantee or its appropriate division’s logo. OSI will abide by grantee’s guidelines for such use.
LETTER OF INTENT (LOI) INSTRUCTIONS

The LOI Project Description can be no more than 10 pages, and it is REQUIRED that you include all of the sections below in this specific order for your LOI to be considered (pages must be numbered consecutively):

1. Trial rationale and expected impact of a successful outcome
2. Hypothesis
3. Objectives (primary, secondary, and exploratory)
4. Endpoints (primary and secondary)
5. Key inclusion/exclusion criteria
6. Summary treatment plan with trial schema
7. Statistical Plan: expected sample size, sample size justification, analysis plan, interim monitoring for futility
8. Data handling and monitoring patient safety
9. Trial sites and labs
10. Description of correlative studies
11. Timeline from grant award to reporting of results: please provide specific timetables for protocol development, regulatory approvals, industry agreements, IRB approvals, activation, accrual, time on study, analysis, and reporting.
12. Budget summary by project year (indirect costs may not exceed 10%)
13. Summary of other anticipated support (Institutional/Philanthropic/Industry/Other)
14. References Cited

In addition to the above, applicants are required to complete the following sections in ProposalCentral:

- Title Page
- Download Templates & Instructions
- Enable Other Users to Access this Proposal
- Applicant/PI
- Institution & Institutional Contacts
- Attachments
  - Biosketch – Applicant/PI (5-page maximum)
  - Project Description (to include all sections listed above in order)
- Signature Page
- Validate
- Submit
FULL PROPOSAL INSTRUCTIONS
Please be sure to address the comments provided to you by the OSI from your LOI submission. Additionally, certain fields on the application in ProposalCentral are pre-populated from your LOI submission. You may leave these as-is, add to, or otherwise modify them.

The Project Description Template can be found on ProposalCentral. It is REQUIRED that you include all of the sections in the specific order for your full proposal to be considered (pages must be numbered consecutively). If a section is not relevant, still include the section title and denote it as not applicable.

Applicants are also required to complete the following sections in ProposalCentral:
1. Title Page
2. Download Templates & Instructions
3. Enable Other Users to Access this Proposal
4. Applicant/PI
5. Institution & Institutional Contacts
6. Key Personnel (list any co-investigators; you may also list a study coordinator(s), research nurse, data manager, or other key personnel on the project)
7. Collaborators (list roles of collaborating individuals, labs, and/or institutions)
8. IRB/IND Approval
9. Intellectual Property
10. Patient Advocacy
11. Budget Period Detail (confusingly, the year for which you are entering data is the one in larger type but not highlighted and the year that appears to be highlighted is the button to move to that year; upload the Budget Justification using section 14 of the web form)
12. Budget Summary
13. Other Support for Research (list only other financial support that is overlapping, supportive, or otherwise directly relevant to your project; we encourage you to demonstrate how other sources of support will create benefit or leverage the conduct of the proposed trial)
14. Proposal Attachments
   • Biosketches (2 to 5 biosketches allowed per application; 5-page maximum per biosketch)
   • Budget Justification (2-page limit per institution)
   • Letters of Support (maximum of 5 letters are allowed)
   • Project Description
   • Project Timeline
   • Protocol/White Paper
   • References Cited (1-page limit)
15. Validate
16. Signature Page(s)
17. Submit
LETTER OF INTENT (LOI) INSTRUCTIONS

The LOI Project Description can be no more than 5 pages, and it is REQUIRED that you include all of the sections below in this specific order for your LOI to be considered (pages must be numbered consecutively):

1. Project rationale and expected impact of a successful outcome
2. Hypothesis
3. Specific aims
4. Statistical plan
5. Research strategy (including protocol/s)
6. Summary budget by project year (indirect costs may not exceed 10%)
7. Summary of other anticipated support (Institutional/Philanthropic/Industry/Other)
8. References Cited

In addition to the above, applicants are required to complete the following sections in ProposalCentral:

- Title Page
- Download Templates & Instructions
- Enable Other Users to Access this Proposal
- Applicant/PI
- Institution & Institutional Contacts
- Attachments
  - Biosketch – Applicant/PI (5-page maximum)
  - Project Description (to include all sections listed above in order)
- Signature Page
- Validate
- Submit
FULL PROPOSAL INSTRUCTIONS
Please be sure to address the comments provided to you by the OSI from your LOI submission. Additionally, certain fields on the application are pre-populated from your LOI submission. You may leave these as-is, add to, or otherwise modify them.

The Project Description Template can be found on ProposalCentral. It is REQUIRED that you include all of the sections in specific order for your full proposal to be considered (pages must be numbered consecutively).

Applicants are also required to complete the following sections in ProposalCentral:
1. Title Page
2. Collaboration/Project Members: please list any Co-PIs. You may also list Project Managers or other key personnel on the project.
3. Download Templates & Instructions
4. Enable Other Users to Access this Proposal
5. Applicant/PI
6. Institution & Institutional Contacts
7. Letters of Support
8. Background, Rationale, & Preliminary Data
9. Budget Period Detail (confusingly, the year for which you are entering data is the one in larger type but not highlighted and the year that appears to be highlighted is the button to move to that year; upload the Budget Justification using section 14 of the web form)
10. Budget Summary
11. Other Financial Support (list only other financial support that is overlapping, supportive, or otherwise directly relevant to your project; we encourage you to demonstrate how other sources of support will create synergistic benefit or leverage the conduct of the proposed project)
12. Proposal Attachments
   - Biosketches (2 to 5 biosketches allowed per application; 5-page maximum per biosketch)
   - Budget Justification (2-page limit per institution)
   - Letters of Support (maximum of 5 letters are allowed)
   - Project Description
   - References Cited (1-page limit)
13. Validate
14. Sign/Print Application
15. Submit
ADDITIONAL RESOURCES

2023-2024 GRANT CYCLE
https://osinst.org/researchers/#grants

NEWSLETTER SIGN UP
https://osinst.org/patients/#sign-up
Sign up as “doctor/researcher” to receive information on our annual grant cycle.

RESEARCHER RESOURCES
https://osinst.org/researchers/

THE FRONTLINE BLOG
https://osinst.org/blog/